In positive early data from the RCT, sacubitril/valsartan given over 24 weeks reduced signs of heart damage in cancer ...

A mixed bag of counterintuitive results hinders trial interpretation, but experts still see actionable results.

One is an siRNA biologic, the other an oral agent, but both lowered Lp(a) levels by 80% or more in ASCVD patients.

A nasal spray would be a workaround for drug resistance seen with oral diuretics, with the potential to reduce hospital ...

Left atrial appendage occlusion (LAAO) appears to be a viable alternative to oral anticoagulation for stroke prevention in select patients undergoing catheter ablation for atrial fibrillation (AF), ...

Part 2 of this 7,000-patient trial suffered from discontinuations and low event rates: still, early MRAs did not impact CV ...

The two strategies, used to reduce renal, brain, and heart injury after surgery, were ineffective, but the story isn’t done.

CHICAGO, IL—For patients with a history of acute MI who are vulnerable to the cardiovascular risks posed by influenza ...

Amidst discrepant SPRINT and ACCORD data, this study confirms the benefits seen in nondiabetics, Shawna Nesbitt says.

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

CHICAGO, IL—Following bioprosthetic valve surgery, anticoagulation with edoxaban (Savaysa; Daiichi Sankyo) is as effective as ...

The improved engagement with HF patients intended to optimize GDMT was very modest, but did lead to increased use of MRAs.